The global Adrenogenital Syndrome Treatment Market is expected to achieve significant growth, reaching a market value of USD 12.81 billion in 2023. With a compound annual growth rate (CAGR) of 5.6% from 2023 to 2033, the market is poised to expand further as innovative treatments and advanced medical procedures continue to gain traction.
The increasing adoption of natural treatments, minimally invasive surgeries, and new therapies is anticipated to be the primary growth driver for the market. These approaches offer more effective and less invasive solutions for patients, improving outcomes and quality of life for those affected by adrenogenital syndrome, also known as congenital adrenal hyperplasia (CAH).
Key Market Insights:
- Market Value in 2023: US$ 12.81 billion
- CAGR (2023-2033): 5.6%
Adrenogenital syndrome is a genetic disorder affecting the adrenal glands, often requiring lifelong management and treatment. The rising focus on developing therapies that reduce complications and improve the ease of managing this condition is expected to play a crucial role in expanding the market. The development of advanced therapeutic interventions, such as hormone replacement therapy (HRT) and gene-based treatments, is likely to further accelerate market growth in the coming years.
The increasing prevalence of genetic testing and early diagnosis also supports the growth of the adrenogenital syndrome treatment market. As awareness about the condition and its treatments grows, patients are gaining access to more effective and personalized treatment options.
Surgically fixing abnormal genital appearances is further expected to enhance the market. Hormonal therapy is also used to replace the hormones that are not produced by the adrenal glands. On a daily basis, patients with chronic atopic diseases are administered corticosteroids or hydrocortisone. As a result of this treatment, the production of androgen will be normalized.
As this syndrome is highly prevalent among children and infants, the market is expected to substantially grow in the coming years. In the early stages of the condition, infants are injected with hormones, with the transition to orally administered hormones after 18 months. CAH patients who receive treatment are most likely to live a normal life. The survival rate for infants without treatment is usually less than six weeks.
Market Competition
Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demands. To ensure that end users are able to benefit from the use of new products and technologies, you must promote them to end users. By forming a strategic partnership, a company can increase the amount of production it can do as a result of an increase in its capacity.
- Spruce Biosciences Inc. and Kaken Pharmaceutical Co. Ltd announced a licensing agreement to develop and commercialize Spruce’s product candidate, tildacerfont, for treating congenital adrenal hyperplasia (CAH). Spruce will receive a $15 million upfront payment from Kaken as part of the agreement, and additional payments are pending upon reaching future development and commercial milestones. In addition to that, tiers of double-digit royalties will be paid on Japanese net sales. For all other geographies, Spruce will retain all rights to tildacerfont, while Kaken will develop and market it in Japan.
- A new Phase 2 study from Neurorocrine Biosciences, Inc. is being presented demonstrating substantial reductions in adrenal androgens and androgen precursors in adolescent patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD). As part of its presentation in Hall A1, the company also provided information regarding patient preferences and treatment patterns for classic CAH.
Key Companies Profiled
- Crystal Pharma
- Monarch Pharmaceuticals, Inc.
- Jubilant Cadista Pharmaceuticals Inc.
- Pfizer CentreOne
- Healthkey Lifescience Pvt. Ltd.
- Zydus Pharmaceuticals
- Praxgen Pharmaceuticals
- Sandoz
- Vintage Labs
- Actavis, Inc.
Key Segments Profiled in the Adrenogenital Syndrome Treatment Market Industry Survey
By Drug Type:
- Mineralocorticoids
- Glucocorticoids
By Route of Administration:
- Oral
- Parenteral
- Intravenous
- Inhaled
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube